Brainscape's Knowledge GenomeTM

Browse over 1 million classes created by top students, professors, publishers, and experts.


See full index

Module 103: The Heart, Lungs and Blood > Theme 3: Lecture 17 - Primary and secondary dyslipidaemias > Flashcards

Theme 3: Lecture 17 - Primary and secondary dyslipidaemias Flashcards

1
Q

According to the Framingham heart study, what are the major CVD risk factors

A
  • High blood pressure
  • High blood cholesterol
  • Smoking
  • Obesity
  • Diabetes
  • Physical inactivity
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Name 3 studies that investigate the risk factors for CVD

A
  • Framingham heart study
  • Cholesterol treatment trialists
  • Copenhagen city heart study
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

What was the aim of the cholesterol treatment trialists study

A

conducting periodic meta-analyses of large-scale (≥1000 participants), long-term (≥2 years treatment duaration) unconfounded, randomized controlled trials of lipid intervention therapies

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

What were the findings of the cholesterol treatment trialists

A
  • Reduction of LDL cholesterol using statin therapy substantially reduces the risk of major vascular events (major coronary events, strokes or the need for coronary revascularization) and vascular mortality
  • Further reductions in LDL cholesterol with more intensive statin therapy produce further reductions in the incidence of major vascular events
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Modifiable risk factors for CVD

A
  • Smoking
  • Obesity
  • Sedimentary lifestyle
  • Diabetes
  • High cholesterol
  • Hypertension
  • Excess alcohol intake
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Un-modifiable risk factors for CVD

A
  • Age > 50
  • Gender
  • Genetic factors
  • Pre-existing CVD
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Name 2 risk calculator tools

A
  • QRISK3

- NICE guidelines

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

What does a QRISK3 over 10 mean

A
  • 10% risk of CVD event over the next ten years

- Primary prevention with lipid lowering therapy (such as statins) should be considered

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Why treat lipid disorders which are often asymptomatic

A
  • To reduce the atherosclerotic process and the incidence of clinical vascular disease.
  • To prevent pancreatitis which is associated with grossly increased serum triglyceride (>10mmol/L, usually >20mmol/L).
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Describe LDLRs

A
  • LDLR is a cell-surface receptor (encoded by LDLR gene) that recognizes ApoB-100 (apolipoproteinB-100) which is embedded in the phospholipid outer layer of LDL particles.
  • Present on most cells but the majority on the liver.
  • LDLR on hepatocytes binds to LDL particles and remove them from the circulation. The LDLR then return to the cell surface to repeat this process.
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

What is the first line treatment for hypercholesterolaemia

A

Statins

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Describe Ezetimibe

A
  • Is a potent and selective inhibitor of absorption of cholesterol in the small bowel.
  • The drug and its active glucuronide metabolite impair the intestinal reabsorption of both dietary and hepatically excreted biliary cholesterol through inhibition of a membrane transporter
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

What is the membrane transporter that Ezetimibe inhibits

A

Niemann-Pick C1-Like 1 (NPC1L1)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Describe PCSK9 inhibitors

A

PCSK9 functions as a binding protein; it is expressed primarily in hepatocytes and after secretion binds to the LDLR and promotes their degradation. By blocking PCSK9, these drugs result in increased availability of LDLR to remove LDLC from the circulation.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

What are the 3 main patterns of lipid profiles in lipoprotein abnormality

A
  • Hypercholesterolaemia
  • Mixed hyperlipidaemia
  • Hypertriglyceridaemia
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Describe the pattern of lipoprotein abnormality in hypercholesterolaemia

A

Raised TC (total cholesterol) and LDLC (LDL cholesterol)

17
Q

Describe the pattern of lipoprotein abnormality in mixed hyperlipidaemia

A

Raised TC and LDLC with raised TG, often low HDLC

18
Q

When is hypercholesterolaemia seen

A

typically seen in familial hypercholesterolaemia (FH)

19
Q

When is mixed hyperlipidaemia seen

A

This pattern is often seen in patients with glucose intolerance and diabetes and arises from the increased production and reduced breakdown of triglyceride-rich lipoproteins

20
Q

Describe hypertriglyceridaemia

A

Pure hypertriglyceridaemia is less common, may be familial and (unlike most other dyslipidaemias), tending to cause harm through acute pancreatitis.

21
Q

What should TC (total cholesterol) be in a healthy adult

A

<5, ideal <4

22
Q

What should TG be in a healthy adult

A

<1.7

23
Q

What should HDLC (HDL cholesterol) be in a healthy adult

A

> 1

24
Q

What should LDLC (LDL cholesterol) be in a healthy adult

A

<3, ideal <2

25
Q

What should non HDL cholesterol be in a healthy adult

A

<2.8, or <2.5 if on statins

26
Q

What is lipoprotein (a)

A

A macromolecular complex, similar to LDL but contains Apolipoprotein (a) as well as Apolipoprotein B

27
Q

What does elevated lipoprotein(a) cause

A

it has been suggested that there is an association between elevated Lp(a) concentrations and myocardial infarction, stroke, and aortic valve stenosis

28
Q

When would you consider measuring Lipoprotein(a)

A
  • Intermediate or high risk of CVD(≥3% over 10 years of fatal CVD and or >10% over 10 years of fatal and non-fatal CVD)
  • Subjects with premature CVD
  • FH cases
  • Fhx of premature CVD or raised LP(a)
  • Recurrent CVD despite on statin treatment
29
Q

Treatments for raised lipoprotein (a)

A
  • Lipid apheresis
  • PCSK9 inhibitors
  • Antisense therapy (Small molecules directly binds to apo(a) mRNA in the nucleus of hepatocytes) - can reduce LP(a) levels by up to 90%.
30
Q

What is lipid apheresis

A

LDL apheresis is a nonsurgical therapy that removes low-density lipoprotein (LDL) cholesterol from a patient’s blood. During LDL apheresis, the plasma portion of the blood, which contains cholesterol, is separated and run through a machine that removes the LDL

31
Q

Describe Familial Hypercholesterolaemia

A
  • Common (1:200-250 ) genetic disordercharacterised by increased Serum LDL-Cholesterol and earlyCVD.
  • Autosomal dominant
  • Mutations in theLDLRgene that encodes theLDLR protein which reduces its function.
  • In a few cases (~ 3%) with the same clinical phenotype; it is either a mutation in ApoB which is the part of LDL that binds with the receptor, or a gain of function mutation in LDL receptor degradation (PCSK9).
32
Q

Clinical presentation of FH

A
  • Tendon xanthoma
  • Corneal arcus
  • Deposits of cholesterol derived from LDL resulting in bumps on the skin
33
Q

What is tendon xanthoma

A

cholesterol deposits in tendons. They appear as slowly enlarging papules or subcutaneous nodules attached to tendons, ligaments, fascia and periosteum

34
Q

What is corneal arcus

A

a deposit of cholesterol, phospholipids, and triglycerides in an “arc” on either the top or bottom side of the iris

35
Q

Treatment for FH

A
  • Low Saturated Fat Diet and exercise
  • Statins
  • Possible addition of cholesterol absorption inhibitor (ezetimibe)
  • Rarely resins/surgery/LDL apheresis
  • Anti–PCSK9
  • Involve patient self help group, offer DNA testing and get the family tested.

Module 103: The Heart, Lungs and Blood (51 decks)

Brainscape helps you reach your goals faster, through stronger study habits.
© 2024 Bold Learning Solutions. Terms and Conditions